Loading...
A216080 logo

JETEMA, Co., Ltd.KOSDAQ:A216080 Stock Report

Market Cap ₩171.7b
Share Price
n/a
1Y-33.8%
7D-5.5%
1D2.0%
Portfolio Value
View

JETEMA, Co., Ltd.

KOSDAQ:A216080 Stock Report

Market Cap: ₩171.7b

JETEMA (A216080) Stock Overview

A bio venture company, engages in the research and development of medicines and medical devices. More details

A216080 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

A216080 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW482,882 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
482,882 investors already sharing narratives

JETEMA, Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for JETEMA
Historical stock prices
Current Share Price₩4,605.00
52 Week High₩11,280.00
52 Week Low₩4,040.00
Beta0.64
1 Month Change-7.34%
3 Month Change-37.43%
1 Year Change-33.84%
3 Year Change-65.95%
5 Year Change-74.09%
Change since IPO6.47%

Recent News & Updates

Analysis Article Jan 15

JETEMA, Co., Ltd.'s (KOSDAQ:216080) 30% Price Boost Is Out Of Tune With Revenues

The JETEMA, Co., Ltd. ( KOSDAQ:216080 ) share price has done very well over the last month, posting an excellent gain...

Recent updates

Analysis Article Jan 15

JETEMA, Co., Ltd.'s (KOSDAQ:216080) 30% Price Boost Is Out Of Tune With Revenues

The JETEMA, Co., Ltd. ( KOSDAQ:216080 ) share price has done very well over the last month, posting an excellent gain...
Analysis Article Nov 14

These 4 Measures Indicate That JETEMA (KOSDAQ:216080) Is Using Debt Extensively

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article Jan 23

Here's Why JETEMA (KOSDAQ:216080) Has A Meaningful Debt Burden

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article Mar 23

JETEMA (KOSDAQ:216080) Is Posting Healthy Earnings, But It Is Not All Good News

Despite posting strong earnings, JETEMA, Co., Ltd.'s ( KOSDAQ:216080 ) stock didn't move much over the last week. We...
Analysis Article Feb 25

Is JETEMA, Co., Ltd.'s (KOSDAQ:216080) Shareholder Ownership Skewed Towards Insiders?

A look at the shareholders of JETEMA, Co., Ltd. ( KOSDAQ:216080 ) can tell us which group is most powerful...
Analysis Article Jan 21

JETEMA (KOSDAQ:216080) Is Carrying A Fair Bit Of Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article Dec 17

The JETEMA (KOSDAQ:216080) Share Price Has Gained 110%, So Why Not Pay It Some Attention?

JETEMA, Co., Ltd. ( KOSDAQ:216080 ) shareholders might be concerned after seeing the share price drop 19% in the last...

Shareholder Returns

A216080KR PharmaceuticalsKR Market
7D-5.5%-1.3%0.8%
1Y-33.8%-10.3%115.9%

Return vs Industry: A216080 underperformed the KR Pharmaceuticals industry which returned -14.5% over the past year.

Return vs Market: A216080 underperformed the KR Market which returned 101.8% over the past year.

Price Volatility

Is A216080's price volatile compared to industry and market?
A216080 volatility
A216080 Average Weekly Movement9.1%
Pharmaceuticals Industry Average Movement6.9%
Market Average Movement9.4%
10% most volatile stocks in KR Market16.7%
10% least volatile stocks in KR Market4.9%

Stable Share Price: A216080 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A216080's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2009265Jeong Sun Namwww.jetema.com

JETEMA, Co., Ltd., a bio venture company, engages in the research and development of medicines and medical devices. It offers clostridium botulinum toxins, fillers, lifting threads for medical treatment, elastin and collagen stimulate solution under Ecolla, and healthy skin care under vitten brand names. The company also provides skin care hyaluronic acid masks.

JETEMA, Co., Ltd. Fundamentals Summary

How do JETEMA's earnings and revenue compare to its market cap?
A216080 fundamental statistics
Market cap₩171.71b
Earnings (TTM)-₩5.07b
Revenue (TTM)₩77.07b
2.2x
P/S Ratio
-33.9x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A216080 income statement (TTM)
Revenue₩77.07b
Cost of Revenue₩39.44b
Gross Profit₩37.63b
Other Expenses₩42.70b
Earnings-₩5.07b

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-136.02
Gross Margin48.83%
Net Profit Margin-6.58%
Debt/Equity Ratio159.4%

How did A216080 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/15 04:18
End of Day Share Price 2026/07/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

JETEMA, Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hyun Jeong SonYuanta Securities Korea Co., Ltd.